Sheba and Datos Health Launch Remote Monitoring Program for Children with Complex Heart Defects

Sheba Medical Center, Israel’s largest medical center and a Newsweek top-10 ranked world’s best hospital for the last three years, today announced the inauguration of a new program from The Heart Institute at Safra Children’s Hospital – a first-of-its-kind clinic in Israel for remote monitoring of children with complex heart defects. The program will use remote monitoring technology provided by Datos Health, a member of Sheba Medical Center’s ARC (Accelerate, Redesign, Collaborate) Telemedicine Hub.

Children who suffer from complex heart malformations require significant early intervention, including a series of surgeries and catheterizations performed from infancy through the first several years of the child’s life, necessitating the involvement of a coordinated multidisciplinary team.

“The first months of life for children with complex heart malformations are characterized by hemodynamic instability and a significant risk to life with high morbidity,” explained Yoav Bolkier, MD, Senior Paediatric Cardiologist of the Paediatric Heart Institute at the Edmond and Lili Safra Children’s Hospital. “The world’s leading centers have implemented remote care programs to enable at-home monitoring of pediatric patients, which has led to a reduction in mortality from 15 percent to less than 5 percent. We are proud to offer this new program to families in Israel and beyond to improve the care and survival of children born with complex heart conditions.”

The team at Datos and ARC, together with clinicians from The Heart Institute, developed the connected platform, which integrates sensors and other inputs to transmit data of infants’ vital signs to the care team. Clinicians will be able to remotely monitor the weight, oxygen saturation, pulse and blood pressure of infants in the program, enabling early detection of changes or aggravation of the infant’s state in real-time from anywhere in the world.

Parents will receive devices for measuring the required parameters as well as a connected tablet through which they can provide daily reports to the care team. The regular contact between parents and care teams in the periods between the physical visits to the clinic will enable early intervention when necessary and reduce infant mortality rates due to these complex heart defects.

“The connected platform developed by the Datos team, supported by ARC, enables Sheba clinicians to maintain transparency on their young, vulnerable patients between hospital visits, enabling more proactive care, and providing a sense of control to parents at such a crucial time,” said Iris Shtein, Co-Director of the telemedicine Hub at ARC. “Being able to provide this program remotely means that we can truly break through physical boundaries and even borders to help those children that need us most.”

The Heart Institute for Children at Safra, together with the Center for Digital Innovation at Sheba, will operate a virtual clinic to support parents of children being treated for complex heart defects from the ultra-Orthodox sector, the Palestinian Authority, the West Bank, Gaza, Iraq, Kurdistan and Cyprus. By utilizing the latest connected technologies developed in ARC by Datos Health, the new program will make it possible to bring Sheba’s doctors to patients’ homes, anytime, anywhere in the world, particularly in countries where such care would otherwise be unavailable.

“This remote monitoring program is another hybrid service ARC has been developing as part of Sheba’s overall strategy to transform healthcare and improve quality, access, and health equity in Israel and around the world,” said Eyal Zimlichman MD, Chief Medical Officer and Chief Innovation Officer at Sheba Medical Center and founder of ARC.

Datos Health, a leader in remote care automation, facilitates the increasing transition of care from the hospital to the home. A robust and flexible, automated remote care platform, the user-friendly yet cost-effective Datos solution enables any hospital department to rapidly and seamlessly build and deploy new remote care processes and workflows.

 

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version